OverviewChartNewsTraderScreen

BNP Paribas Discount Zert NOVN 29.../  DE000PC56WR9  /

EUWAX
2024-05-02  9:28:12 AM Chg.+0.04 Bid5:20:00 PM Ask5:20:00 PM Underlying Strike price Expiration date Option type
76.14EUR +0.05% -
Bid Size: -		 -
Ask Size: -		 NOVARTIS N - CHF 2025-12-29 Call
GlobeNewswire 5:01 PM Genmab Announces Financial Results for the First Quarter of 2024
GlobeNewswire 2:01 PM STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disord...
GlobeNewswire 2:00 PM Vicinitas Therapeutics Appoints Adam Hughes as Chief Scientific Officer
TeleTrader 2:00 PM Novartis to acquire Mariana Oncology for $1.7B
GlobeNewswire 9:00 AM Ikerian AG, Parent Company of RetinAI U.S. Inc. Announces Final Close of USD 6.18M (CHF 5.65M) Serie...
TeleTrader 04-23 Novartis up 5% on upbeat guidance, earnings
TeleTrader 04-23 Novartis EPS up 28% to $1.31 in Q1
GlobeNewswire 04-16 Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
TeleTrader 04-11 Novartis launches offer for Morphosys at €68 per share
TeleTrader 04-09 Novartis to reduce workforce by 680 in Product Development
GlobeNewswire 03-14 IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
TeleTrader 03-12 Germany clears Novartis' MorphoSys $2.9B deal
GlobeNewswire 02-28 Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
TeleTrader 02-05 Novartis to acquire MorphoSys for $2.9B
TeleTrader 01-31 Novartis net sales up 8% to $11.4B in Q4
GlobeNewswire 01-10 Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire 01-05 Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...
GlobeNewswire 01-02 Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...
GlobeNewswire 2023-12-21 Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire 2023-12-19 Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, N...
GlobeNewswire 2023-12-11 Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and ...
GlobeNewswire 2023-12-08 Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broa...
GlobeNewswire 2023-12-06 Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement i...
TeleTrader 2023-11-28 Novartis expects 5% annual sales growth until 2027
GlobeNewswire 2023-11-20 Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH